Eton Pharmaceuticals (ETON) Common Equity (2019 - 2025)
Historic Common Equity for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $23.1 million.
- Eton Pharmaceuticals' Common Equity rose 4470.93% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.1 million, marking a year-over-year increase of 4470.93%. This contributed to the annual value of $24.4 million for FY2024, which is 5783.42% up from last year.
- Per Eton Pharmaceuticals' latest filing, its Common Equity stood at $23.1 million for Q3 2025, which was up 4470.93% from $24.0 million recorded in Q2 2025.
- Eton Pharmaceuticals' Common Equity's 5-year high stood at $24.4 million during Q1 2025, with a 5-year trough of $11.2 million in Q3 2022.
- Its 5-year average for Common Equity is $17.2 million, with a median of $16.0 million in 2024.
- Per our database at Business Quant, Eton Pharmaceuticals' Common Equity soared by 102824.21% in 2021 and then plummeted by 3791.23% in 2022.
- Eton Pharmaceuticals' Common Equity (Quarter) stood at $17.6 million in 2021, then fell by 25.82% to $13.1 million in 2022, then grew by 18.34% to $15.5 million in 2023, then soared by 57.83% to $24.4 million in 2024, then dropped by 5.33% to $23.1 million in 2025.
- Its last three reported values are $23.1 million in Q3 2025, $24.0 million for Q2 2025, and $24.4 million during Q1 2025.